Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;9:971108. doi: 10.3389/fcvm.2022.971108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Mapelli, Mattavelli, Salvioni, Banfi, Ghilardi, De Martino, Gugliandolo, Mantegazza, Volpato, Basile, Branco Pires, Sassi, Nusca, Vignati, Contini, Sforza, Biondi, Perrone Filardi and Agostoni.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Sacubitril/Valsartan effects on sleep apneas. In the whole population we observed a significant reduction in CSA (see text) with no differences in AHI from baseline to the end of follow-up (left panel). In patients with CSA at baseline (n = 22) a significant reduction of CSA was obtained after Sacubitril/Valsartan therapy (right panel). Data presented as medians and interquartile ranges. AHI: apnea hypopnea index; CSA: central sleep apneas. *Analysis conducted only on patients with CSA>0 at baseline (n = 22).